Elia E, Iannaccone M, D'Ascenzo F, et al. - Researchers assessed Impella in terms of its short term safety as well as efficacy in high risk percutaneous coronary intervention (HR-PCI) population. They analyzed all studies describing short term results of PCI with any Impella device. This study involved nine studies with 7448 patients. Impella 2.5 was found to be the most frequently employed axial flow pump used to support these PCIs (88.7%). In 5.09% of patients, in-hospital deaths occurred, while vascular complications and post-procedural stroke occurred in 2.53% and 2.77% of patients, respectively. Episodes of major bleeding were experienced by 5.98% of patients, and 4.44% had post-procedural dialysis. Overall, an acceptable rate of complication, especially concerning vascular complications and major bleedings, seemed associated with the use of Impella in high risk PCI.